Development of a RIPK1 degrader to enhance antitumor immunity

Xin Yu(Baylor College of Medicine), Jin Wang(Baylor College of Medicine)

Nature Communications

December 16, 2024

10.1038/s41467-024-55006-2

Cited by 25

Related Papers

Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry

|Nature Communications|2020|204

Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug

|PLoS ONE|2015|38

MCU complex: Exploring emerging targets and mechanisms of mitochondrial physiology and pathology

|Journal of Advanced Research|2024|34

Enhancing Intracellular Accumulation and Target Engagement of PROTACs with Reversible Covalent Chemistry

|bioRxiv (Cold Spring Harbor Laboratory)|2019|20

COOKIE-Pro: covalent inhibitor binding kinetics profiling on the proteome scale

|Nature Communications|2025|3